Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials

• Egile Nagusiak: Qingfang Li (Egilea), Li Cheng (Egilea), Kai Shen (Egilea), Hongyu Jin (Egilea), Hui Li (Egilea), Yuan Cheng (Egilea), Xuelei Ma (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2019-06-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: B-cell leukemia/lymphoma-2 (BCL-2) protein is an important part of apoptotic pathway, which is overexpressed in chronic lymphocytic leukemia cells, non-Hodgkin lymphoma cells, and myeloma cells. Venetoclax (ABT-199/GDC-0199) is a highly selective bioavailable inhibitor of BCL-2 protein,...